JP2011504874A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504874A5 JP2011504874A5 JP2010520356A JP2010520356A JP2011504874A5 JP 2011504874 A5 JP2011504874 A5 JP 2011504874A5 JP 2010520356 A JP2010520356 A JP 2010520356A JP 2010520356 A JP2010520356 A JP 2010520356A JP 2011504874 A5 JP2011504874 A5 JP 2011504874A5
- Authority
- JP
- Japan
- Prior art keywords
- vertebrate
- target gene
- chylomicron
- nucleic acid
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 16
- 108010004103 Chylomicrons Proteins 0.000 claims 9
- 230000014509 gene expression Effects 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 229940122498 Gene expression inhibitor Drugs 0.000 claims 7
- 108010004942 Chylomicron Remnants Proteins 0.000 claims 6
- 150000002632 lipids Chemical class 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 235000003642 hunger Nutrition 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- -1 antagomir Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 108091008104 nucleic acid aptamers Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000006863 thiophosphorylation reaction Methods 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99079607P | 2007-11-28 | 2007-11-28 | |
| US60/990,796 | 2007-11-28 | ||
| PCT/JP2008/003523 WO2009069313A1 (en) | 2007-11-28 | 2008-11-28 | System for delivering nucleic acids for suppressing target gene expression by utilizing endogenous chylomicron |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504874A JP2011504874A (ja) | 2011-02-17 |
| JP2011504874A5 true JP2011504874A5 (cg-RX-API-DMAC7.html) | 2012-01-19 |
| JP5429884B2 JP5429884B2 (ja) | 2014-02-26 |
Family
ID=40678225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520356A Active JP5429884B2 (ja) | 2007-11-28 | 2008-11-28 | 内因性カイロミクロンを利用した、標的遺伝子の発現を抑制する核酸のデリバリーシステム |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8329670B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2215229B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5429884B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101874111B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009069313A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9731025B2 (en) | 2010-08-20 | 2017-08-15 | National University Corporation Tokyo Medical And Dental University | Pharmaceutical composition for transcolonic absorption |
| CN102198276B (zh) * | 2011-04-01 | 2013-03-27 | 山西医科大学 | 乳糜微粒作为肝脏靶向基因治疗载体的应用 |
| CN102198277A (zh) * | 2011-04-01 | 2011-09-28 | 山西医科大学 | 一种基因治疗肝癌的双靶向性载体及其制备方法 |
| CN104178515B (zh) * | 2013-05-21 | 2018-08-31 | 成都先导药物开发有限公司 | 一种化合物的细胞透膜的方法 |
| EP3029059B1 (en) * | 2013-05-21 | 2018-07-04 | Hitgen Ltd. | Compound administration precursor and medicament carrier preparation |
| WO2015066027A2 (en) | 2013-10-28 | 2015-05-07 | Dots Devices, Inc. | Allergen detection |
| JP2015199264A (ja) | 2014-04-08 | 2015-11-12 | ブラザー工業株式会社 | 液体吐出装置 |
| US10487103B2 (en) | 2015-03-24 | 2019-11-26 | Gifu University | Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them |
| WO2017094745A1 (ja) * | 2015-12-01 | 2017-06-08 | 国立大学法人大阪大学 | 核酸を含む経腸投与用組成物 |
| EP4005602A4 (en) | 2019-07-30 | 2024-06-12 | Shionogi & Co., Ltd | NUCLEIC ACID AGENT TARGETED AGAINST MURF1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4331670A1 (de) * | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| DE4338704A1 (de) * | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
| CA2264012C (en) * | 1996-08-13 | 2011-04-26 | Chiron Corporation | Compositions and methods for polynucleotide delivery |
| US7615539B2 (en) * | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
| JP2005168485A (ja) | 2003-11-20 | 2005-06-30 | Tsutomu Suzuki | ｓｉＲＮＡの設計方法 |
| JP4706019B2 (ja) | 2005-07-08 | 2011-06-22 | 国立大学法人東京農工大学 | アプタマーの同定方法 |
-
2008
- 2008-11-28 WO PCT/JP2008/003523 patent/WO2009069313A1/en not_active Ceased
- 2008-11-28 JP JP2010520356A patent/JP5429884B2/ja active Active
- 2008-11-28 EP EP08853348.4A patent/EP2215229B1/en not_active Not-in-force
- 2008-11-28 CN CN200880117687XA patent/CN101874111B/zh not_active Expired - Fee Related
-
2010
- 2010-05-26 US US12/787,552 patent/US8329670B2/en active Active
-
2012
- 2012-11-05 US US13/668,668 patent/US8507458B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504874A5 (cg-RX-API-DMAC7.html) | ||
| ES2537568T3 (es) | Nuevos fármacos para inhibición de la expresión genética | |
| Hatakeyama et al. | The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice | |
| Weiss et al. | MicroRNAs in ischemia-reperfusion injury | |
| JP6023126B2 (ja) | 標的遺伝子の発現を抑制する組成物 | |
| Michell et al. | HDL and microRNA therapeutics in cardiovascular disease | |
| WO2014022739A3 (en) | Modified rnai agents | |
| WO2011153493A3 (en) | Biodegradable lipids for the delivery of active agents | |
| US11312954B2 (en) | Transkingdom platform for therapeutic nucleic acid delivery | |
| CN101874111B (zh) | 利用内源性乳糜微粒递送用于抑制靶基因表达的核酸的体系 | |
| JP2022501064A (ja) | ケイ素を含有するカチオン性脂質 | |
| WO2016145008A2 (en) | Mirna for treatment of breast cancer | |
| Tian et al. | The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice | |
| de Fougerolles et al. | siRNA and the lung: research tool or therapeutic drug? | |
| Zhou et al. | MicroRNA-21 abrogates palmitate-induced cardiomyocyte apoptosis through caspase-3/NF-κB signal pathways | |
| US20110293653A1 (en) | Antagonists of mir-155 for the treatment of inflammatory liver disease | |
| Gedefaw et al. | Targeting inflammasome activation in COVID-19: delivery of RNA interference-based therapeutic molecules | |
| Abdel Rhman et al. | The role of microRNAs in the pathophysiology, diagnosis, and treatment of diabetic cardiomyopathy | |
| Karkhane et al. | Oncogenesis and tumor inhibition by microRNAs and its potential therapeutic applications: a systematic review | |
| Ungaro et al. | PEI-engineered respirable particles delivering a decoy oligonucleotide to NF-κB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cells | |
| JP5685764B2 (ja) | ミトコンドリア機能向上剤 | |
| EP3238727B1 (en) | Non-aggregating immunostimulatory oligonucleotides | |
| Ballarín-González et al. | Clinical translation of RNAi-based treatments for respiratory diseases | |
| US20220267769A1 (en) | Medical uses, methods and uses | |
| JP7431728B2 (ja) | ＥＮａＣ発現の調節因子 |